Core Insights - The inclusion of the HPV vaccine in the national immunization program starting November 10, 2025, aims to provide free vaccinations to girls born after November 10, 2011, who are at least 13 years old [1] Group 1: HPV Vaccine Market Dynamics - The launch of the domestic nine-valent HPV vaccine offers a comprehensive and accessible option for cervical cancer prevention among eligible women [2] - There has been a notable increase in both consultation and vaccination rates for the domestic nine-valent HPV vaccine across various provinces, indicating growing acceptance and demand [2][4] - The domestic nine-valent HPV vaccine is perceived to have comparable efficacy and safety to imported versions, supported by large-scale clinical trials [2][3] Group 2: Factors Influencing Vaccine Uptake - The affordability of the domestic nine-valent HPV vaccine has significantly influenced the willingness of individuals to choose it over more expensive alternatives [3] - Public trust in domestic vaccines is increasing due to their proven safety, effectiveness, and established technology, leading to a shift in preference towards domestic options [3][4] - Government initiatives, including the "Accelerating the Elimination of Cervical Cancer Action Plan (2023-2030)," are promoting HPV vaccination and providing practical support for eligible girls [3] Group 3: Future Outlook - With ongoing policy support and increasing public acceptance, the domestic nine-valent HPV vaccine is expected to see rising consultation and vaccination rates, enhancing its reputation [4] - The expansion of supply, coverage areas, and improvement of grassroots vaccination services will further enhance accessibility and affordability for eligible women [4]

Core Viewpoint - The HPV vaccine, crucial for preventing cervical cancer in women, is gaining attention in China, with discussions on its inclusion in national immunization programs and local public health initiatives [1][6]. Group 1: Current Policies and Implementation - Sixteen provinces in China have introduced policies for HPV vaccination, with Beijing offering free vaccinations for eligible schoolgirls starting this autumn [2][3]. - The implementation plan in Beijing specifies the use of domestically produced bivalent HPV vaccines for girls aged 9 to 14, following a specific immunization schedule [2]. Group 2: Public Health Impact - HPV infection is responsible for 80-90% of cervical cancer cases, which ranks as the third most common cancer among women aged 15-44 in China [2]. - The call for government-funded vaccinations has been growing, with initiatives already covering over a million eligible girls in Jiangxi province [3]. Group 3: Challenges in Vaccine Accessibility - Economic disparities across regions pose challenges to the expansion of HPV vaccination programs, with approximately 42% of provinces offering free vaccinations [4]. - The average procurement price of HPV vaccines has decreased by 50-70% due to competitive procurement processes, which could enhance accessibility [4][5]. Group 4: Need for National Immunization Inclusion - Experts advocate for the inclusion of the HPV vaccine in the national immunization program to ensure equitable access for all children, regardless of their economic background [6][7]. - The World Health Organization has set a target for 90% vaccination coverage among girls aged 9-14 by 2030, highlighting the urgency for national policy changes [6][7].